SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 26, 2003; DOI 10.1182/blood-2002-11-3325. This Article Full Text (PDF) All Versions of this Article: 2002-11-3325v1 102/8/3025    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Saunthararajah, Y. Articles by Barrett, A J Search for Related Content PubMed PubMed Citation Articles by Saunthararajah, Y. Articles by Barrett, A J Social Bookmarking                   What's this? Submitted November 5, 2002 Accepted June 19, 2003 A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome Yogen Saunthararajah*, Ryotaro Nakamura, Robert Wesley, Qiong J Wang, and A J Barrett Hematology/Oncology, University of Illinois at Chicago, Chicago, IL, USA Hematology, National Heart, Lung and Blood Institute, Bethesda, MD, USA * Corresponding author; email: yogen{at}uic.edu. Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can be used to treat the cytopenia associated with myelodysplastic syndrome. Previously, we identified HLA DR15, younger age and shorter duration of red cell transfusion dependence as pretreatment variables that correlate significantly with a response. Using these pre-treatment variables we have devised a simple method to prospectively identify patients with low or high probabilities of response to immunosuppression. The ability of this system to predict response was confirmed in a separate cohort of 23 MDS patients treated with immunosuppression. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. M. Stone How I treat patients with myelodysplastic syndromes Blood, June 18, 2009; 113(25): 6296 - 6303. [Full Text] [PDF] M. E.D. Chamuleau, T. M. Westers, L. van Dreunen, J. Groenland, A. Zevenbergen, C. M. Eeltink, G. J. Ossenkoppele, and A. A. van de Loosdrecht Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome Haematologica, April 1, 2009; 94(4): 496 - 506. [Abstract] [Full Text] [PDF] E. M. Sloand, C. O. Wu, P. Greenberg, N. Young, and J. Barrett Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy J. Clin. Oncol., May 20, 2008; 26(15): 2505 - 2511. [Abstract] [Full Text] [PDF] S. D. Nimer Myelodysplastic syndromes Blood, May 15, 2008; 111(10): 4841 - 4851. [Abstract] [Full Text] [PDF] E. Estey Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1908 - 1915. [Abstract] [Full Text] [PDF] M. Melchert and A. F. List Management of RBC-Transfusion Dependence Hematology, January 1, 2007; 2007(1): 398 - 404. [Abstract] [Full Text] [PDF] M. Battiwalla, T. Hahn, M. Radovic, H. Roy, A. Wahab, E. Duman, R. Bajwa, S. Padmanabhan, J. Becker, A. J. Barrett, et al. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence Blood, March 1, 2006; 107(5): 1970 - 1973. [Abstract] [Full Text] [PDF] D. P. Steensma and J. M. Bennett The Myelodysplastic Syndromes: Diagnosis and Treatment Mayo Clin. Proc., January 1, 2006; 81(1): 104 - 130. [Abstract] [Full Text] [PDF] E. M. Sloand, L. Mainwaring, M. Fuhrer, S. Ramkissoon, A. M. Risitano, K. Keyvanafar, J. Lu, A. Basu, A. J. Barrett, and N. S. Young Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome Blood, August 1, 2005; 106(3): 841 - 851. [Abstract] [Full Text] [PDF] D. P. Steensma and A. F. List Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity Mayo Clin. Proc., May 1, 2005; 80(5): 681 - 698. [Abstract] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020